Rituximab-related viral infections in lymphoma patients

被引:261
作者
Aksoy, Sercan [1 ]
Harputluoglu, Hakan [1 ]
Kilickap, Saadettin [1 ]
Dede, Didem Sener [1 ]
Dizdar, Omer [1 ]
Altundag, Kadri [1 ]
Barista, Ibrahim [1 ]
机构
[1] Hacettepe Univ, Dept Med Oncol, Ankara, Turkey
关键词
rituximab; non-Hodgkin's lymphoma; viral infections;
D O I
10.1080/10428190701411441
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recently, a human/mouse chimeric monoclonal antibody, rituximab, has been successfully used to treat cases of B-cell non-Hodgkin's lymphoma and some autoimmune diseases. However, several viral infections related to rituximab have been reported in the literature, but were not well characterized. To further investigate this topic, relevant English language studies were identified through Medline. There were 64 previously reported cases of serious viral infection after rituximab treatment. The median age of the cases was 61 years (range: 21 - 79). The median time period from the start of rituximab treatment to viral infection diagnosis was 5.0 months (range: 1 - 20). The most frequently experienced viral infections were hepatitis B virus (HBV) (39.1%, n = 25), cytomegalovirus infection (CMV) (23.4%, n = 15), varicella-zoster virus (VZV) ( 9.4%, n = 6), and others (28.1%, n = 18). Of the patients with HBV infections, 13 (52.0%) died due to hepatic failure. Among the 39 cases that had viral infections other than HBV, 13 died due to these specific infections. In this study, about 50% of the rituximab-related HBV infections resulted in death, whereas this was the case in only 33% of the cases with other infections. Close monitoring for viral infection, particularly HBV and CMV, in patients treated with rituximab should be recommended.
引用
收藏
页码:1307 / 1312
页数:6
相关论文
共 61 条
[41]   Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy [J].
Rossi, G ;
Pelizzari, A ;
Motta, M ;
Puoti, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) :58-62
[42]   Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO) [J].
Sandherr, M. ;
Einsele, H. ;
Hebart, H. ;
Kahl, C. ;
Kern, W. ;
Kiehl, M. ;
Massenkeil, G. ;
Penack, O. ;
Schiel, X. ;
Schuettrumpf, S. ;
Ullmann, A. J. ;
Cornely, O. A. .
ANNALS OF ONCOLOGY, 2006, 17 (07) :1051-1059
[43]   Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20 [J].
Sansonno, D ;
De Re, V ;
Lauletta, G ;
Tucci, FA ;
Boiocchi, M ;
Dammacco, F .
BLOOD, 2003, 101 (10) :3818-3826
[44]  
Sarrecchia Cesare, 2005, Journal of Infection and Chemotherapy, V11, P189, DOI 10.1007/s10156-005-0385-z
[45]   Diabetes insipidus due to herpes encephalitis in a patient with diffuse large cell lymphoma. A case report [J].
Scheinpflug, K ;
Schalk, E ;
Reschke, K ;
Franke, A ;
Mohren, M .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2006, 114 (01) :31-34
[46]   Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab [J].
Sera, Toshiki ;
Hiasa, Yoichi ;
Michitaka, Kojiro ;
Konishi, Ichiro ;
Matsuura, Kana ;
Tokumoto, Yoshio ;
Matsuura, Bunzo ;
Kajiwara, Takeshi ;
Masumoto, Toshikazu ;
Horiike, Norio ;
Onji, Morikazu .
INTERNAL MEDICINE, 2006, 45 (11) :721-724
[47]   Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab [J].
Sharma, VR ;
Fleming, DR ;
Slone, SP .
BLOOD, 2000, 96 (03) :1184-1186
[48]   Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP:: a diagnostic and therapeutic challenge [J].
Skrabs, C ;
Müller, C ;
Agis, H ;
Mannhalter, C ;
Jäger, U .
LEUKEMIA, 2002, 16 (09) :1884-1886
[49]   Hepatitis B reactivation in a patient receiving radiolabeled rituximab [J].
Soong, YL ;
Lee, KM ;
Lui, HF ;
Chow, WC ;
Tao, M ;
Loong, SLE .
ANNALS OF HEMATOLOGY, 2005, 84 (01) :61-62
[50]   Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma [J].
Stroffolini, T ;
Andriani, A ;
Bibas, M ;
Barlattani, A .
ANNALS OF HEMATOLOGY, 2002, 81 (01) :48-49